Analystreport

Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors